Journal: OncoTargets and Therapy

Article Title:

CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors

doi: 10.2147/ott.s278736

Figure Lengend Snippet: Figure 2 CD26 expression in paratumoral tissues, benign pancreatic tumors, low- grade malignant pancreatic tumors and high-grade malignant pancreatic tumors. * represented P<0.05, *** represented P <0.001.

Article Snippet: After washing in PBS three times, the sections were blocked with goat serum (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) at 37°C for 1 h, followed by incubation with primary rabbit polyclonal anti-DPPIV antibodies (1:1200; cat. no. NB100-59021; Novus Biologicals, USA) overnight at 4° C. Unconjugated primary antibody was then removed by washing in PBS, and ready-to-use EnVision reagent (EnVision Detection System Peroxidase/DAB, Rabbit/ Mouse; Dako, Denmark) was used to bind the primary antibody.

Techniques: Expressing

Journal: OncoTargets and Therapy

Article Title:

CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors

doi: 10.2147/ott.s278736

Figure Lengend Snippet: Figure 1 Typical cytoplasmic staining of CD26 in (A) PDAC; (B) SPT; (C) NEN; (D) paratumoral pancreatic tissue; (E) IPMN; (F) serous neoplasms; (G) pancreatitis; (H) acinar cell neoplasm; (I) secondary pancreatic metastasis from oviduct serous adenocarcinoma and (J) MCN. The upper ones of each figure were ×100, and the lower ones were ×200.

Article Snippet: After washing in PBS three times, the sections were blocked with goat serum (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) at 37°C for 1 h, followed by incubation with primary rabbit polyclonal anti-DPPIV antibodies (1:1200; cat. no. NB100-59021; Novus Biologicals, USA) overnight at 4° C. Unconjugated primary antibody was then removed by washing in PBS, and ready-to-use EnVision reagent (EnVision Detection System Peroxidase/DAB, Rabbit/ Mouse; Dako, Denmark) was used to bind the primary antibody.

Techniques: Staining

Journal: OncoTargets and Therapy

Article Title:

CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors

doi: 10.2147/ott.s278736

Figure Lengend Snippet: Figure 3 Higher CD26 expression was associated with poorer DFS and OS in malignant pancreatic tumor patients. According to CD26 expression level, all the malignant pancreatic tumor patients were divided into high expression group and low expression group. Kaplan-Meier survival analysis and Log rank test showed that patients with lower CD26 expression had a better (A) disease-free survival and (B) overall survival than those with higher CD26 expression (P=0.048 and P=0.024).

Article Snippet: After washing in PBS three times, the sections were blocked with goat serum (Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd.) at 37°C for 1 h, followed by incubation with primary rabbit polyclonal anti-DPPIV antibodies (1:1200; cat. no. NB100-59021; Novus Biologicals, USA) overnight at 4° C. Unconjugated primary antibody was then removed by washing in PBS, and ready-to-use EnVision reagent (EnVision Detection System Peroxidase/DAB, Rabbit/ Mouse; Dako, Denmark) was used to bind the primary antibody.

Techniques: Expressing